Abstract: A chromium-containing catalyst is disclosed which includes both ZnCr2O4 and crystalline ?-chromium oxide. The ZnCr2O4 contains between about 10 atom percent and 67 atom percent of the chromium in the composition and at least about 70 atom percent of the zinc in the composition, and at least about 90 atom percent of the chromium present as chromium oxide in the composition is present as ZnCr2O4 or crystalline ?-chromium oxide. Also disclosed are a method for preparing this composition comprising ZnCr2O4 and crystalline ?-chromium oxide; and a chromium-containing catalyst composition prepared by treatment of the composition comprising ZnCr2O4 and crystalline ?-chromium oxide with a fluorinating agent.

Abstract: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Abstract: Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.

Abstract: The invention relates to dicopper(I) oxalate complexes stabilized by neutral Lewis bases, such as alkenes or alkynes, and to the use of dicopper(I) oxalate complexes as precursors for the deposition of metallic copper, in which the neutral Lewis bases used are alkynes, alkenes, triarylphosphines, CO or isonitriles.

Abstract: The invention relates to a process for ketalizing triacetonamine by reacting triacetonamine and a hydroxyl derivative, for example, a mono- or polyhydric alcohol, with gaseous hydrogen chloride to give an open-chain or cyclic ketal.

Abstract: One object of the present invention is to provide a drug that is effective in treatments for and prevention of psychiatric disorders and in treatments for and prevention of neurological diseases, inhibiting a Group II metabotropic glutamate receptor. The object is solved by a 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative represented by formula [I]: (wherein R1 and R2 are the same or different, and each represents a hydrogen atom, C1-10alkyl group, etc; X represents a hydrogen atom or a fluorine atom; and Y represents an amino group, —SR3, —S(O)nR7, —SCHR3R4, —S(O)nCHR3R4, —NHCHR3R4, —N(CHR3R4)(CHR5R6), —NHCOR3 or —OCOR7), a pharmaceutically acceptable salt thereof, or a hydrate thereof and so on.

Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.

Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6, NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiolo

Abstract: The disclosure herein relates to organofunctional silanes and mixtures of organofunctional silanes possessing mercaptan and hydrocarbyl and/or heterocarbyl functionality. These silanes reduce or eliminate the generation of volatile organic compounds (VOC's) during use, aid in the processing of filled elastomeric materials and enhance the end-use properties of the filled elastomer. The present disclosure relates to the composition of these silanes.

Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.

Abstract: 2,5-dihydroxyterephthalic acid is produced in high yields and high purity from 2,5-dihaloterephthalic acid by contact with a copper source and a ligand that coordinates to copper under basic conditions.

Abstract: A sulfide chain-bearing organosilicon compound having the average compositional formula: (R1O)(3-p)(R2)pSi—R3—S—(R4—Sm)q—R4—S—R3—Si(OR1)(3-p)(R2)p is prepared at low costs and in high yields by reacting a halogen-terminated organosilicon compound having the formula: (R1O)(3-p)(R2)pSi—R3—S—R4—X, and optionally a halide having the formula: X—R4—X and/or sulfur with an aqueous solution or dispersion of a polysulfide M2Sn or hydrate thereof in the presence of a phase transfer catalyst. R1 and R2 are monovalent C1-4 hydrocarbon groups, R3 and R4 are divalent C1-10 hydrocarbon groups, m has an average value of 2-6, n has an average value of 2-6, p is 0, 1 or 2, q is 1, 2 or 3, X is halogen, and M is ammonium or alkali metal.

Abstract: The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.

Abstract: The present invention relates to a process for preparing optionally substituted arylsulphonic anhydrides of the general formula (I)

Abstract: Polymerizable fluorinated ester compounds having formulae (1) and (2) are novel wherein R1 is H, methyl or trifluoromethyl, R2 and R3 are H or a monovalent hydrocarbon group, R2 and R3 may form a ring, R4 is H, OH or a monovalent hydrocarbon group, and R5 is an acid labile group.

Abstract: Ester compounds having formula (1) wherein R1 is fluorine or C1-C10 fluoroalkyl, R2 is C1-C10 alkylene or fluoroalkylene, and R3 is an acid labile group are novel. They can be polymerized into polymers which are used to formulate resist compositions, which are processed by the lithography involving ArF exposure, offering many advantages including improved resolution and transparency, minimal line edge roughness, improved etch resistance, and especially minimal surface roughness after etching.

Abstract: A water-stable and water-soluble ceramic precursor is provided, containing at least one Group III element. Also, a metal acid salt complex is provided comprising (1) bismuth, lanthanum, and titanium, and (2) a polyether acid. In addition, methods are provided for preparing the Group III metal acid salt complex and the Bi, La, Ti acid salt complex comprising a bismuth polyether acid salt complex, a lanthanum polyether acid salt complex, and a titanium polyether acid salt complex. Finally, devices that include lanthanum-doped bismuth titanate as the active component are provided, as well as a water-stable and water-soluble gallium polyether acid complex.

Abstract: A silsesquioxane compound mixture having a high proportion of silsesquioxane compounds bearing bulky substituent groups on side chain and having a degree of condensation of substantially 100% is prepared by a first stage wherein a silane feed comprising a trifunctional silane bearing a bulky substituent group on side chain represented by formula (1): wherein Y is an aliphatic or aromatic organic group optionally having a functional group, X1, X2 and X3 are H, halogen, alkoxy or aryloxy is hydrolyzed in the presence of an acid or base catalyst, and a second stage wherein dehydrating condensation is carried out in the presence of a strong base catalyst while removing the water resulting from condensation out of the reaction system.

Abstract: A method for producing high purity terephthalic acid wherein a slurry having an acetic acid solvent and, dispersed therein, crude terephthalic acid crystals which has been prepared by subjecting a p-alkyl benzene to a liquid phase oxidation in a solvent of acetic acid is continuously converted to a water slurry by the mother liquid exchange, and then the resultant water slurry is subjected to a hydrogenation treatment, which comprises introducing the above acetic acid slurry to a tower having a center axis having a plurality of agitating blades at the top thereof, to form a region having a high concentration of terephthalic acid crystals in the tower through the sedimentation of the terephthalic acid crystals, supplying the water for substitution to the bottom of the tower in such a manner to form an upward water flow while generating a revolving flow of the high concentration region by the rotation of the agitation blade, to thereby subject said terephthalic acid crystals and said upward water flow to a coun

Abstract: The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.